New Alliance

New Alliance Capital is a venture capital and private equity firm that specializes in early, growth stage and pre-IPO investments. It primarily invest in high-end manufacturing, technology, advanced agriculture, consumer goods, information, media, energy, recycling, environmental protection, and modern services industry sectors. New Alliance Capital typically invests between $4.71 million and $31.41 million. Qu Liefeng founded it in 2008, with its headquarters in Shanghai in China.

Liefeng Qu

Founder

Nan Zhang

Executive Director

Past deals in Mongolia

Innoviz Technologies Ltd.

Series C in 2019
Innoviz is a manufacturer of solid-state LiDAR sensors and perception software that enable the mass-production of autonomous vehicles. InnovizPro is a solid-state LiDAR that offers outstanding performance and value for automotive and other applications. InnovizOne is a cutting-edge, automotive-grade LiDAR sensor that provides superior 3D sensing for Level 3-Level 5 autonomous driving. The company is backed by top-tier strategic partners and investors, including Magna International, Samsung, Aptiv, Magma Venture Partners, Vertex Ventures, SoftBank Ventures Asia, China Merchants Capital (SINO-BLR Industrial Investment Fund, L.P.), 360 Capital Partners, Glory Ventures, Naver, Shenzhen Capital Group, New Alliance Capital, Harel Insurance Investments and Financial Services, Phoenix Insurance Company, and others.

ZStack

Series B in 2020
ZStack Cloud Platform has served more than 1,000 enterprise users and established ecological and channel partnerships with more than 200 cloud vendors, covering government, finance, education, internet, energy, manufacturing and many other industries.
CapitalBio Technology Co., Ltd., a life science company, develops and commercializes health-care solutions. Its products CapitalBio respiratory pathogens nucleic acid detection kit; designed for detection of the infection of respiratory pathogens, CapitalBio genotype and drug resistance detection kit for Hepatitis B Virus (HBV); designed for a genotyping of subtypes of HBV and detection of drug resistance and interferon, CapitalBio Thalassemia gene mutations detection kit; designed for genotyping of Thalassemia, and other products are broad spectrum of microarray and microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding. The company’s services include Special Needs Plans (SNP) service, mRNA Expression Profiling Service, DNA (Deoxyribonucleic acid) methylation detection service, and sequencing services. CapitalBio Technology Co., Ltd. was founded in 2012 and is based in Beijing, China. CapitalBio Technology Co., Ltd. operates as a subsidiary of CapitalBio Corporation.

Biotheus Inc.

Series B in 2021
Biotheus is a biotech company that focuses on the discovery and development of antibody-based therapeutics. The core areas of research and development include tumor immunotherapy, metabolic disease treatment, and other domestic diseases. Andy Tsun, Joanne Sun, and Xiaolin Liu established the biotech company in Zhuhai, Guangdong in 2018.
Beijing Advaccine Biotechnology Co., Ltd. engages in discovery of new vaccines, both preventive and therapeutic. The company product pipeline consists respiratory syncytial virus (RSV) vaccine, type1 diabetes( T1D) therapeutic vaccine, and hepatitis B virus (HBV) therapeutic vaccine. Its vaccines help in inducing immuno-tolerance and T-cell stimulation for certain diseases. The company is based in Beijing, China.

Biotheus Inc.

Series B in 2020
Biotheus is a biotech company that focuses on the discovery and development of antibody-based therapeutics. The core areas of research and development include tumor immunotherapy, metabolic disease treatment, and other domestic diseases. Andy Tsun, Joanne Sun, and Xiaolin Liu established the biotech company in Zhuhai, Guangdong in 2018.
Beijing Advaccine Biotechnology Co., Ltd. engages in discovery of new vaccines, both preventive and therapeutic. The company product pipeline consists respiratory syncytial virus (RSV) vaccine, type1 diabetes( T1D) therapeutic vaccine, and hepatitis B virus (HBV) therapeutic vaccine. Its vaccines help in inducing immuno-tolerance and T-cell stimulation for certain diseases. The company is based in Beijing, China.

ZStack

Series B in 2018
ZStack Cloud Platform has served more than 1,000 enterprise users and established ecological and channel partnerships with more than 200 cloud vendors, covering government, finance, education, internet, energy, manufacturing and many other industries.

Sight Diagnostics

Series B in 2016
Sight Diagnostics Ltd., a medical device company, develops a platform for diagnosing blood diseases using computer vision technology. The company offers Parasight, a malaria detection device that identifies, enumerates, and speciates malaria. Its device makes use of a staining solution and microscopy platform that is applied to various blood diseases and tests. The company is based in Tel Aviv, Israel.

Innoviz Technologies Ltd.

Series C in 2019
Innoviz is a manufacturer of solid-state LiDAR sensors and perception software that enable the mass-production of autonomous vehicles. InnovizPro is a solid-state LiDAR that offers outstanding performance and value for automotive and other applications. InnovizOne is a cutting-edge, automotive-grade LiDAR sensor that provides superior 3D sensing for Level 3-Level 5 autonomous driving. The company is backed by top-tier strategic partners and investors, including Magna International, Samsung, Aptiv, Magma Venture Partners, Vertex Ventures, SoftBank Ventures Asia, China Merchants Capital (SINO-BLR Industrial Investment Fund, L.P.), 360 Capital Partners, Glory Ventures, Naver, Shenzhen Capital Group, New Alliance Capital, Harel Insurance Investments and Financial Services, Phoenix Insurance Company, and others.

Banma Kuaipao

Series C in 2017
Banma Kuaipao develops a mobile application for freight transportation. It also operates mobile applications to book cabs and buses for travelling. Li Jia founded Banman Kuaipao in July 2015. Its headquarters is in Wuhan in China.

ShopEx

Series D in 2017
ShopEx is an e-commerce software and service provider in China. It focuses on the research and development of e-commerce software and provision of related solutions and services. ShopEx has become the largest and most experienced professional team and develops e-commerce software with independent core technology and intellectual property rights and services.
Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds. The company's technologies provide integrated control solutions, including the use of technical expertise to optimize the process and increase protein expression to reduce production scale, providing bio-pharmaceutical companies with personalized, chemical-defined cell culture media, formula production, technical support and ancillary services.

QST corporation

Series B in 2020
Shanghai QST Corporation engages in the design, research and development of MEMS sensors and smart applications for intelligent mobile terminals and IoT applications. The company designs and manufactures high quality sensor products and customizes intelligent applications and services for its clients. Since the company’s foundation in September 2012, it has achieved rapid growth based on the virtual IDM model and using the domestic industrial support system in China. Main products are accelerometers, magnetic sensors, barometers, gyroscopes, light sensors, combined inertial sensors and related intelligent application systems.

Sight Diagnostics

Series D in 2020
Sight Diagnostics Ltd., a medical device company, develops a platform for diagnosing blood diseases using computer vision technology. The company offers Parasight, a malaria detection device that identifies, enumerates, and speciates malaria. Its device makes use of a staining solution and microscopy platform that is applied to various blood diseases and tests. The company is based in Tel Aviv, Israel.
Lynk Pharmaceuticals (Hangzhou) Co., Ltd. is engaged in the development of small molecule drugs for tumors and autoimmune diseases through new drug research, sales, patent authorization and patent transfer. The firm was founded in 2017 and is headquartered in China.

InnoStar Semiconductor

Seed Round in 2021
InnoStar Semiconductor is a semiconductor storage technology service company.

Chubao

Series D in 2017
CooTek (NYSE: CTK), founded in 2008, listed on NYSE on September 28th, 2018, is a global and fast-growing mobile internet company that develops innovative mobile apps and artificial intelligence technology. With a massive global user base, CooTek aims to empower users to express themselves and enjoy relevant content seamlessly. CooTek’s flagship mobile app, TouchPal Keyboard, uses unparalleled technology to provide the best input experience to both Android and iPhone users. CooTek has also developed many content-rich apps, spanning across 5 selected verticals including fitness, lifestyle, healthcare, news and short videos, and entertainment. In September 2018, CooTek’s global products reached an average of 213.7 million monthly active users around the world. Headquartered in Shanghai, CooTek offices can be found in Silicon Valley, Beijing, Taipei, Guangzhou, and Shenzhen. Today, CooTek has over 170 patent applications and granted patents worldwide and continually pursue excellence in technology innovation and intellectual property development. CooTek has also established its own big data development center and AI lab in Silicon Valley. Many academic papers written by CooTek have been used in discussions at world-renowned big data and AI conferences such as AAAI, KDD and CIKM.
CapitalBio Technology Co., Ltd., a life science company, develops and commercializes health-care solutions. Its products CapitalBio respiratory pathogens nucleic acid detection kit; designed for detection of the infection of respiratory pathogens, CapitalBio genotype and drug resistance detection kit for Hepatitis B Virus (HBV); designed for a genotyping of subtypes of HBV and detection of drug resistance and interferon, CapitalBio Thalassemia gene mutations detection kit; designed for genotyping of Thalassemia, and other products are broad spectrum of microarray and microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding. The company’s services include Special Needs Plans (SNP) service, mRNA Expression Profiling Service, DNA (Deoxyribonucleic acid) methylation detection service, and sequencing services. CapitalBio Technology Co., Ltd. was founded in 2012 and is based in Beijing, China. CapitalBio Technology Co., Ltd. operates as a subsidiary of CapitalBio Corporation.

CF PharmTech, Inc.

Series E in 2020
CF PharmTech, Inc. develops and manufactures inhalation products. The company’s products include metered dose inhaler (MDI), dry powder inhalers (DPI), nasal sprays, nebulizer, and respiratory medicines. It provides contract manufacturing organization (CMO) services. It conducts research and development in the areas of asthma, chronic obstructive pulmonary disease (COPD), and rhinitis. The company was founded in 2007 and is based in Suzhou, China.
Shenzhen Jiedian Technology is a mobile device power bank rental start-up.

Sight Diagnostics

Series C in 2019
Sight Diagnostics Ltd., a medical device company, develops a platform for diagnosing blood diseases using computer vision technology. The company offers Parasight, a malaria detection device that identifies, enumerates, and speciates malaria. Its device makes use of a staining solution and microscopy platform that is applied to various blood diseases and tests. The company is based in Tel Aviv, Israel.

Tavotek Biotherapeutics

Series A in 2021
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.

Biotheus Inc.

Series D in 2021
Biotheus is a biotech company that focuses on the discovery and development of antibody-based therapeutics. The core areas of research and development include tumor immunotherapy, metabolic disease treatment, and other domestic diseases. Andy Tsun, Joanne Sun, and Xiaolin Liu established the biotech company in Zhuhai, Guangdong in 2018.